Axitinib SR is under clinical development by Alcon and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase II drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Axitinib SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Axitinib SR overview

Axitinib (AR-14034) is under development for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema. It is administered through intravitreal route as implant. AR-14034 is a sustained-release retinal implant containing the pan-VEGF inhibitor axitinib formulated in a unique bio-erodible polymer blend using PRINT technology.

Alcon overview

Alcon is engaged in the development and manufacturing of devices in the field of ophthalmology. The company’s portfolio encompasses contact lenses and surgical products, including implantables, consumables and surgical equipment. The company’s products are indicated for the treatment of various conditions such as cataracts, glaucoma, retinal diseases and refractive errors. It conducts clinical trials to evaluate the safety and efficacy of its products for the prevention and cure of blindness and different eye diseases. Alcon’s pipeline products are developed through collaboration with institutions, medical innovators, research advisors and academic thought leaders. The company has operations in the Americas, Europe, the Middle East, and Africa and Asia Pacific. Alcon is headquartered in Fribourg, Switzerland.

For a complete picture of Axitinib SR’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.